PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Stopped early · Phase 4

Conditions studied: Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism

In brief

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

Key facts

Study ID

NCT03006562

Run by

Johns Hopkins University

People needed

501

Starts

2017-07-01

Expected to finish

2019-11-01

Last updated by the study team

2020-08-05

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP
• Patients who would have otherwise been eligible to receive routine post-RP care

You may not qualify if…

• Active treatment for VTE
• Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)
• Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
• Epidural analgesia
• Spinal anesthesia
• Participation in a different trial that increases a patient's risk of VTE

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.